Kyowa Hakko Kirin Co., Limited

Kirin Beer Kabushiki Kaisha

E. R. Squibb Sons, Inc.

Medarex Inc.

Kirin Pharma Kabushiki Kaisha

Kirin Holdings Kabushiki Kaisha

Teikyo Heisei University

Kirin Brewery Company, Limited

Mitsubishi Heavy Industries Mechatronics Systems, Ltd.

Hematech, LLC

Isao Ishida

Kazuma Tomizuka

Yoshimi Kuroiwa

Hitoshi Yoshida

James M Robl

Nils Lonberg

Edward L Halk

Mitsuo Oshimura

Kazunori Hanaoka

Barbara A Osborne

Richard A Goldsby

Poothappillai Kasinathan

Ikuko Taira

Stacy E Ferguson

Takeshi Nishikawa

Yuichiro Taira

Seiji Kobayashi

Hideo Suzuki

Akihiro Iwamatsu

Seiichi Terakura

Philippe Collas

Toshiya Ogawa

Masaharu Yoshioka

Naoyuki Umemoto

Eddie Sullivan

Yoshimi Okada

Makoto Kakitani

Masaaki Yoshikawa

Naoto Yamaoka

Ed Halk

Kazuma c/o Discovery Research Laboratories Kirin Pharma Kabushiki Kaisha Tomizuka

P Kasinathan

An object of the present invention is to effectively induce cancer cell apoptosis using the anti-TRAIL-R1 antibody(ies) and the anti-TRAIL-R2 antibody(ies) and to reduce the toxicity imposed on normal cells. The present invention relates to recombinant obligate anaerobic Gram-positive bacteria that include a nucleic acid encoding a fusion protein having 3 or more anti-TRAIL-R1 single-chain antibodies and/or 3 or more anti-TRAIL-R2 single-chain antibodies, in an expressible state.

Recombinant obligate anaerobic Gram-positive bacteria

The present invention relates to a human artificial chromosome which is genetically transmissible to the next generation with high efficiency and the method for using the same. More specifically, the present invention relates to: a human artificial chromosome in which an about 3.5 Mb to about 1 Mb region containing an antibody &#x3bb; light chain gene derived from human chromosome 22 is bound to a chromosome fragment which is transmissible to a progeny through a germ line of a non-human animal, said chromosome fragment is derived from another human chromosome; a non-human animal carrying the human artificial chromosome and an offspring thereof; a method for producing the non-human animal; a method for producing a human antibody using the nonhuman animal or an offspring thereof; and a human antibody-producing mouse carrying the human artificial chromosome.

Human artificial chromosome containing human antibody lambda light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmission

Recombinant obligate anaerobic gram-positive bacteria

The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.

Transgenic transchromosomal rodents for making human antibodies

Human artificial chromosome containing human antibody &#x3bb; light chain gene and non-human animal containing the human artificial chromosome  capable of genetic transmission

A biomass hydrothermal decomposition apparatus includes, a biomass feeder () that feeds biomass material () under normal pressure to under increased pressure, a hydrothermal decomposition device (A) that allows the fed biomass material () to be gradually moved inside a device main body (A) from either end thereof in a consolidated condition, and also allows hot compressed water () to be fed from an other end of a feed section for the biomass material into the main body (A), so as to cause the biomass material () and the hot compressed water () to countercurrently contact with each other and undergo hydrothermal decomposition, and that elutes a lignin component and a hemicellulose component into the hot compressed water, so as to separate the lignin component and the hemicellulose component from the biomass material (); and a biomass discharger () that discharges, from the side where the hot compressed water is fed into the device main body, a biomass solid residue () under increased pressure to under normal pressure.

Biomass hydrothermal decomposition apparatus, method thereof, and organic material production system using biomass material

Transgenic trasnchromosomal rodents for making human antibodies

The present invention relates to a method for producing a modified foreign chromosome(s) or a fragment(s) thereof, which comprises the steps of: (a) preparing a microcell comprising a foreign chromosome(s) or a fragment(s) thereof, and transferring said foreign chromosome(s) or a fragment(s) into a cell with high homologous recombination efficiency through its fusion with said microcell; (b) in said cell with high homologous recombination efficiency, inserting a targeting vector by homologous recombination into a desired site of said foreign chromosome(s) or a fragment(s) thereof, and/or a desired site of a chromosome(s) derived from said cell with high homologous recombination efficiency, thereby marking said desired site; and (c) in said cell with high homologous recombination efficiency, causing deletion and/or translocation to occur at the marked site of said foreign chromosome(s) or a fragment(s) thereof.

Method for modifying chromosomes

The specification relates to a method for producing a chimeric non-human animal, which comprises preparing a microcell containing a foreign chromosome(s) or a fragment(s) thereof and transferring the foreign chromosome(s) or fragment(s) thereof into a pluripotent cell by fusion with the microcell; a chimeric non-human animal which can be produced by the above method and its progeny; tissues and cells derived therefrom; and a method for using the same. Further, a pluripotent cell containing a foreign chromosome(s) or a fragment(s) thereof, a method for producing the same, and a method for using the same are also provided. Moreover, a pluripotent cell in which at least two endogenous genes are disrupted, and a method for producing the same by homologous recombination are provided.

Isolated human chromosome 14 fragment encoding immunoglobulin genes

In general, the invention features genetically modified non-human mammals (e.g., bovines and other ungulates), and methods of making these mammals. In particular, the invention features transgenic ungulates having reduced levels of endogenous IgM heavy chain and/or prion protein.

Method of producing xenogenous antibodies using a bovine

The invention provides cloned transgenic ungulates (e.g., bovines) in which prion protein activity is reduced by one or more genetically engineered mutations. Desirably, these transgenic bovines are also genetically modified to express xenogenous (e.g., human) antibodies. Because of their resistance to prion-related diseases such as bovine spongiform encephalopy (also known as mad cow disease), these bovines are a safer source of human antibodies for pharmaceutical uses and a safer source of agricultural products.

Transgenic bovine having reduced prion protein activity and uses thereof

The invention features novel methods for the production of large quantities of xenogenous antibodies, such as human antibodies. Preferably, this result is effected by inactivation of IgM heavy chain expression and, optionally, by inactivation of Ig light chain expression, and by the further introduction of an artificial chromosome which results in the expression of xenogenous antibodies (e.g., non-bovine antibodies), preferably human antibodies.

Transgenic ungulates capable of human antibody production

Growing community of inventors

Kanagawa, Japan

Isao Ishida